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Thomas Rivers and the EAE model
 
In the early 1930s, Thomas Rivers and colleagues provided the first evidence 
that immune cells can attack the brain. Their simple experiments established 
what is now the most well-studied model of autoimmunity—the experimental 
autoimmune encephalomyelitis (EAE) model of multiple sclerosis.
 
Early vaccinations against viral diseases
such as rabies occasionally resulted in
“paralytic accidents”—central nervous
system (CNS) complications in which
inflammatory cells invaded the brain
and demyelinating lesions ensued (1).
These complications were widely attrib-
uted to an incomplete inactivation of
the vaccine virus, which was grown in
rabbit brain tissues. But there was another
possible explanation: repeated injections
of brain tissue might have triggered an
allergic reaction.
 
Rabbit brains and Rhesus monkeys
 
Studies had shown that injection of for-
eign brain tissues into the brains of rabbits
could cause paralysis (2). Intrigued, Riv-
ers—then a virologist at The Rockefeller
Institute—set out to duplicate these stud-
ies in monkeys. Rivers and his colleagues
injected Rhesus macaques with normal
brain extracts from rabbits and showed
that most of the monkeys developed
acute CNS disease with immune cell in-
filtration and demyelinating lesions. No
infectious agent could be cultured from
the animals, putting to rest suspicions of
an infectious etiology. Rivers’ group also
noted that the disease-inducing capacity
of the brain extracts paralleled their mye-
lin content, providing the first hint that
myelin was involved in disease induction.
Thus, the experimental allergic (now
“autoimmune”) encephalomyelitis (EAE)
model was born. The group published
these observations in three articles in the
 
Journal of Experimental Medicine
 
 (3–5).
 
Time-saving measures
 
Rivers’ groundbreaking experiments
were cumbersome and time consum-
ing, requiring multiple injections (up to
85 per animal) over a period of a year.
Elvin Kabat (Columbia University) later
fast-tracked the disease process by com-
bining brain extracts with the adjuvant
recently developed by Jules Freund.
This combination induced disease after
only a single injection (6). Another im-
portant finding made by Kabat’s group
and also by Isabel Morgan (Johns Hop-
kins University) was that disease could
be reproduced using brain extracts from
genetically homologous monkeys—the
first indication that an autoimmune
process was at work (6, 7).
 
Deciphering mechanisms
 
Kabat—who was probably the first to
note the similarities between EAE and
MS—had speculated that antibodies spe-
cific for the injected brain material were
to blame for the disease. Over a decade
later, however, T cells emerged as the
primary instigators of EAE. The transfer
of spleen cells, but not antibody, trig-
gered the CNS disease in rats (8), and re-
moval of the thymus from newborn rats
prevented the development of EAE later
in life (9). Thanks to decades of research
conducted by an impressive cast of char-
Demyelination in the parietal lobe of a Rhesus 
macaque. Image reproduced from Rivers et al. (3).
 
acters (for review see reference 10), the
pathology of EAE is now known to in-
volve multiple aspects of the immune re-
sponse including CD4
 
 
 
 T cells, antibod-
ies, complement, and chemokines.
 
EAE branches out
 
Many versions of the EAE model now
exist, which vary both in the strategies
used to evoke disease and in the result-
ing pathology. Critics of the EAE model
question whether this animal model is
truly reflective of human MS, as many
EAE models trigger a specific acute syn-
drome, whereas most human disease in-
volves cycles of relapse and remission.
Vijay Kuchroo (Harvard University) de-
fends the EAE model, pointing out that
“each model recapitulates a small piece
of the human disease,” and has provided
valuable insights into the human disease.
Lawrence Steinman (Stanford Univer-
sity) seconds Kuchroo’s sentiments, add-
ing, “To say that EAE has little to do
with MS would be to ignore that two
approved treatments for MS [Copaxone
and Tysabri] were developed as a result
of experiments in the EAE model.”
The EAE model has also shaped the
modern day evaluation of vaccines by
contributing to the understanding of
how a vaccine, independent of the or-
ganism it is intended to generate immu-
nity against, can sometimes have devas-
tating side effects.
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